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Atrazine (ATR; 2-chloro-4-ethylamino-6-iso-
propylamino-s-triazine), a chlorinated mem-
ber of the family of s-substituted triazines, is
one of the most widely employed herbicides
in the world, with an estimated 76.4 million
pounds used annually in the United States
alone. It acts to suppress photosynthesis by
inhibiting electron transfer at the reducing site
of chloroplast complex II (Eldridge et al.
1999). Although it has limited solubility in
water, ATR is frequently detected in ground
and surface waters in agricultural regions
(Colborn and Short 1999). Studies also reveal
that ATR can be transported into the home,
presumably tracked by soil (Lioy et al. 2000).
Human exposure has been confirmed
(Adgate et al. 2001; Clayton et al. 2003), and,
in fact, approximately 60% of the U.S. popu-
lation is exposed to ATR (Birnbaum and
Fenton 2003). Recent reports indicate that
acute dietary exposures range from 0.234 to
0.857 µg/kg/day, and corresponding figures
for chronic dietary exposure are 0.046 to
0.286 µg/kg/day, considering all commodi-
ties with U.S. Environmental Protection
Agency (EPA) tolerances and drinking water
(Gammon et al. 2005). Occupational expo-
sure to ATR, as measured in mixer-loader-
tender applicators, was reported to be
approximately 2.8 mg ATR/day of work, with
an absorbed dose of 1.8–6.1 µg/kg/day based
on a 5.6% dermal absorption rate (Gammon
et al. 2005). An earlier study of manufacturing
workers reported a total ATR exposure of
10–700 µmol (~ 2.157–151.004 mg) per
work shift (Catenacci et al. 1993).
The understanding of the potential of
ATR to serve as a contributing factor to
human disease and dysfunction is currently
extremely limited. Epidemiologic studies
have linked environmental and/or occupa-
tional ATR exposure to increased mortality
(Sathiakumar et al. 1996), and to non-
Hodgkin’s lymphoma (MacLennan et al.
2003; Sathiakumar and Delzell 1997).
In experimental models, however, a grow-
ing experimental literature documents deleteri-
ous hormonal and reproductive system effects
of ATR. In rodents, reported effects include
reductions in testosterone levels; increases in tri-
iodothyronine (Friedmann 2002; Stoker et al.
2000, 2002); suppression of immune function
(Rooney et al. 2003), of luteinizing hormone
(LH), and of prolactin surges (Cooper et al.
2000); the appearance of mammary gland
tumors; a disruption of regular ovarian cycles;
and the induction of pseudopregnancies
(Cooper et al. 1996; Laws et al. 2000).
The effects of ATR on ovarian function in
female rats have been ascribed to changes in
function of catecholamines in the hypothala-
mus, speciﬁcally decreases in norepinephrine
(NE) and increases in dopamine (DA) in this
region (Cooper et al. 1998). In correspon-
dence with this observation, in vitro studies in
PC12 cells show concentration-dependent
decreases in intracellular DA after exposure to
12.5–200 µM ATR for 6, 12, 18, and 24 hr
and decreases in NE release and intracellular
NE concentrations after exposures to 100 and
200 µM ATR for 12, 18, and 24 hr (Das et al.
2000, 2003). In addition, reductions in the
expression of DA β-hydroxylase [but not of
tyrosine hydroxylase (TH)] were observed.
The inhibitory effects of ATR on intracellular
NE content and NE release, but not on DA
intracellular content, were reversed when
PC12 cells were co-incubated with ATR and
agents known to enhance transcription, phos-
phorylation, or activity of TH and DA
β-hydroxylase, such as 8-bromo-cAMP,
forskolin, or dexamethasone (Das et al. 2003).
These findings suggest that ATR could dis-
rupt catecholamine metabolism by altering its
biosynthetic enzymes.
The fact that ATR can adversely affect
hypothalamic catecholamine systems has
notable implications because such effects
would be unlikely to be restricted to this par-
ticular region, but could affect brain cate-
cholamine systems more generally and thus
affect pathways critical to the control of move-
ment (nigrostriatal dopaminergic systems) and
of complex cognitive functions (mesocortico-
limbic dopaminergic systems). If so, then ATR
exposures may also serve as a risk factor for
neurodegenerative diseases and/or dysfunctions
associated with these systems, which include
Parkinson’s disease, schizophrenia, and atten-
tion deﬁcit disorder, among others (Crossman
2000; Epstein et al. 1999; Viggiano et al.
2003). Indeed, epidemiologic studies have
linked pesticides to an increased odds ratio for
Parkinson’s disease (Breysse et al. 2002), and
various pesticides that affect catecholaminergic
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The widespread use of atrazine (ATR) and its persistence in the environment have resulted in
documented human exposure. Alterations in hypothalamic catecholamines have been suggested as
the mechanistic basis of the toxicity of ATR to hormonal systems in females and the reproductive
tract in males. Because multiple catecholamine systems are present in the brain, however, ATR
could have far broader effects than are currently understood. Catecholaminergic systems such as
the two major long-length dopaminergic tracts of the central nervous system play key roles in
mediating a wide array of critical behavioral functions. In this study we examined the hypothesis
that ATR would adversely affect these brain dopaminergic systems. Male rats chronically exposed
to 5 or 10 mg/kg ATR in the diet for 6 months exhibited persistent hyperactivity and altered
behavioral responsivity to amphetamine. Moreover, when measured 2 weeks after the end of expo-
sure, the levels of various monoamines and the numbers of tyrosine hydroxylase-positive (TH+)
and -negative (TH–) cells measured using unbiased stereology were reduced in both dopaminergic
tracts. Acute exposures to 100 or 200 mg/kg ATR given intraperitoneally to evaluate potential
mechanisms reduced both basal and potassium-evoked striatal dopamine release. Collectively,
these studies demonstrate that ATR can produce neurotoxicity in dopaminergic systems that are
critical to the mediation of movement as well as cognition and executive function. Therefore,
ATR may be an environmental risk factor contributing to dopaminergic system disorders, under-
scoring the need for further investigation of its mechanism(s) of action and corresponding assess-
ment of its associated human health risks. Key words: atrazine, dopamine, hypothalamus,
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http://dx.doi.org/ [Online 24 February 2005]systems have been shown to produce character-
istics of Parkinson’s disease in experimental
models (Betarbet et al. 2000; Reeves et al.
2003; Thiruchelvam et al. 2000b).
The potential for neurotoxic effects of ATR
in vivo, however, particularly chronic effects,
has received almost no experimental attention.
Oral exposure of rats to 1,000 mg/kg ATR for
4–11 days decreased rearing in the open ﬁeld
(Ugazio et al. 1991), whereas acute exposure
of rats to 100 mg/kg decreased spontaneous
Purkinje cell ﬁring rate and cerebellar poten-
tials evoked by electrical stimulation (Podda
et al. 1997).
The objective of the present study was to
evaluate the potential for sustained low-level
ATR exposure to affect two critical cate-
cholamine pathways of the brain: the nigro-
striatal DA pathway, involved in the mediation
of movement (Crossman 2000), and the
mesocorticolimbic DA pathway critical to
complex cognitive functions (Clark et al. 2004;
Remy and Samson 2003). For this purpose, we
evaluated locomotor activity across the course
of exposure, whereas monoamine levels in
striatum, prefrontal cortex, nucleus accum-
bens, and hypothalamus and stereologic cell
counts of TH-positive (TH+) and TH-negative
(TH–) cells in the midbrain were evaluated
2 weeks after cessation of exposure. Further,
this study sought to determine mechanisms by
which any changes in dopaminergic function
in these pathways might be produced by exam-
ining the acute effects of ATR on striatal DA
release using microdialysis.
Materials and Methods
Chronic ATR Exposure
Subjects, exposure, and experimental design.
Thirty male Long-Evans rats purchased from
Taconic Farms (Germantown, NY) were
housed individually in plastic cages in a tem-
perature- and humidity-controlled vivarium
room with a 12-hr dark/light cycle (lights on
0600 hr). Food intake was restricted to main-
tain body weights at 300 g, and water was
available ad libitum during the entire experi-
ment. In our experience, this protocol sus-
tains health and viability to a greater degree
than does ad libitum feeding. At 9 months of
age, exposure to 0, 5, or 10 mg/kg ATR
mixed in food was initiated with continuation
of ad libitum access to distilled drinking
water. These doses of ATR were chosen based
on reports for the rat of an oral median lethal
dose (LD50) of 1,869 mg/kg (U.S. EPA
2001), a no observed adverse effect level
(NOAEL) of 3.3 mg/kg/day, and a lowest
observed adverse effect level (LOAEL) of
34.5 mg/kg/day for this route of administra-
tion measured as body weight loss. A chronic
dietary NOAEL of 1.8 mg/kg/day and
LOAEL of 3.65 mg/kg/day were also reported
(U.S. EPA 2001). We recorded body weights
and food consumption periodically over the
entire duration of the experiment. All proce-
dures were carried out in accord with National
Institutes of Health and University of
Medicine and Dentistry of New Jersey Animal
Use and Care Committee Guidelines
(Institute of Laboratory Animal Resources
1996). The experimental design is summa-
rized in Figure 1A.
We recorded locomotor activity at 2, 3,
and 6 months of ATR exposure and 2 weeks
after cessation of exposure. At the 2-month
time point, we measured locomotor activity
on 3 consecutive days, with animals receiving
an intraperitoneal (ip) injection of saline
5 min before the session during the first
2 days, and an injection of d-amphetamine
sulfate (1 mg/kg) on day 3. Only a single loco-
motor activity session was carried out at the 3-
and 6-month time points and at 2 weeks after
the termination of ATR exposure. Locomotor
activity was recorded during the light phase
(from 0900 hr to 1300 hr) of the light/dark
cycle using methods described below.
Two weeks after cessation of ATR expo-
sure, rats were sacriﬁced by decapitation, brains
were removed, and hypothalamus, prefrontal
cortex, nucleus accumbens, and striatum were
dissected on ice and frozen for HPLC analysis.
The remaining tissue was postfixed in 4%
paraformaldehyde for immunohistochemistry
and stereologic counts.
Locomotor activity measurement. Each rat
was individually placed in an automated loco-
motor activity chamber equipped with infrared
photobeams (Opto-Varimex Minor; Columbus
Instruments International Corporation,
Columbus, OH). Horizontal, vertical, and
ambulatory activities were simultaneously meas-
ured and data were collected over the course of
a 45-min session.
Measurement of monoamine levels. Tissues
were sonicated in 0.1N perchloric acid and
centrifuged. Supernatants were stored at –80°C
until analyzed for monoamine content. Pellets
were digested in 0.5 M sodium hydroxide for
measurements of protein concentration using
reagents from Bio-Rad (Hercules, CA).
We measured monoamines and their
metabolites using HPLC with electrochemical
detection as described elsewhere (Thiruchelvam
et al. 2000a). Brieﬂy, a Waters pump 515 plus
autosampler (Waters Corporation, Milford,
MA) was joined to a chromatographic column
(Alltech Associates Inc, Deerfield, IL). The
amperometric potential was set at 600 mV
relative to the silver/silver chloride, and the
sensitivity of the detector was set at 100 ρA
(microdialysates) or 1 ηA (tissue samples). The
mobile phase was an isocratic 0.1 M mono-
basic phosphate solution containing 0.5 mM
sodium octyl sulfate, 0.03 mM EDTA, and
12–14% vol/vol methanol. Results generated
by these determinations were analyzed with the
Empower Pro program (Empower Software,
Waters Corporation) and are expressed in
picograms per milliliter of microdialysate or
nanograms per milligram of protein of tissue.
DA turnover was expressed as the ratio of
dihydroxyphenylacetic acid (DOPAC) to DA.
Tyrosine hydroxylase immunohistochemis-
try. Five randomly selected paraformaldehyde-
ﬁxed brains from each treatment group were
cut into 30-µm sections, collected in cryo-
protectant, and stored at –20°C for immuno-
labeling studies. Sections were rinsed with
0.1 M phosphate buffer (PB), blocked with
10% normal goat serum for nonspeciﬁc bind-
ing, and incubated in TH primary antibody
(Chemicon, Tamecula, CA) for 48 hr at a dilu-
tion of 1:3,500 in PB with 0.3% Triton X-100
and 10% normal goat serum. Sections were
then incubated with a secondary antibody
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Figure 1. Experimental designs for the chronic ATR exposure component of the study (A) and for acute
ATR exposure for microdialysis studies (B). Abbreviations: MC, methylcellulose; SNpc, substantia nigra
pars compacta.1:200 (Vector Laboratories Inc., Burlingame,
CA) overnight. Sections were washed and
incubated with avidin-biotin solution from
Vectastain ABC reagents (Vector Laboratories)
for 1 hr and developed in 3–3´-diaminobenzi-
dine tetrachloride and H2O2 in 0.05 M Tris
buffer. Sections were counterstained with cre-
syl violet after TH staining. We counted total
numbers of TH+ and Nissl-stained neurons
(TH–) in substantia nigra pars compacta
(SNpc) and the ventral tegmental area (VTA)
using the optical fractionator method as
described below.
Stereologic analysis. After delineation of
the SNpc and VTA at low magniﬁcation (4×
objective), one side of every fourth section
from the entire midbrain region was sampled
at higher magniﬁcation (100× objective) using
the stereology module of the Stereo Investi-
gator imaging program (MicroBrightField Inc.,
Williston, VT) with an Olympus Provis micro-
scope (Olympus America, Melville, NY). We
used the optical fractionator method, an unbi-
ased quantitative technique, for counting TH+
(TH+ and cresyl violet+ neurons) and TH–
(cresyl violet+ only) cells. Criteria for TH+ and
TH– neurons were determined as previously
described (Barlow et al. 2004; Thiruchelvam
et al. 2004). We determined the mean thick-
ness by measuring two ﬁelds from ﬁve sections
per sample, and the entire depth of ﬁeld was
sampled, ignoring the upper and lower 0.5 µm.
All samples were evaluated by one experi-
menter without knowledge of treatment status.
Chemicals. ATR at 98% purity was pur-
chased from Chem Services Inc. (West Chester,
PA). Reagents for microdialysis, HPLC analy-
sis, methylcellulose, and cresyl violet were pur-
chased from Sigma (St. Louis, MO).
Acute ATR Exposure
Subjects, exposure, and experimental design.
Thirty male Long Evans rats weighing between
270 and 320 g purchased from Taconic Farms
were habituated to constant standard labora-
tory conditions of humidity, temperature,
and dark/light cycle (lights on 0600 hr) as
described above. As shown in Figure 1B, we
used microdialysis to evaluate changes in stri-
atal DA release after acute intraperitoneal (ip)
exposures to ATR in sessions lasting 7 hr.
Surgery. After a habituation period of at
least 1 week, rats were anesthetized with pen-
tobarbital (30–40 mg/kg ip) and every 30 min
thereafter received an injection of atropine sul-
fate (0.3 mg/kg ip) to avoid respiratory failure
during the cannula implantation. Once anes-
thetized (assessed by absence of corneal
reflex), the rat was placed in a stereotaxic
apparatus (Kopf Instruments, Tujunga, CA),
the skull was exposed, and a hole was drilled
for placement of a guide cannula (MD-2250;
Bioanalytical Systems Inc., West Lafayette,
IN) over the right striatum, using stereotaxic
coordinates (anterior-posterior, +1.0 mm,
medio-lateral, –2.0 mm with reference to
bregma, dorso-ventral, –3.4 mm from flat
skull) according to the atlas of Paxinos and
Watson (1986). The cannula was ﬁxed to the
skull with anchor screws and acrylic cement.
After surgery, rats were individually housed for
a recovery period of 5–7 days with food
restricted to keep body weight at 300 g and
water was available ad libitum.
Microdialysis. A probe of concentric design
(MD-2262, tip 2 mm; Bioanalytical Systems,
Inc.) was inserted into the guide cannula. The
dialysis probe was continuously perfused at a
ﬂow rate of 2.5 µL/min through a liquid swivel
from an automated system (Bioanalytical
Systems Inc.) with a physiologic Ringer’s solu-
tion containing 147 mM NaCl, 4.0 mM KCl,
1.2 mM CaCl2, and 1 mM MgCl2, pH
6.0–6.5. Sample collection occurred every
30 min. The first hour of sampling was dis-
carded to avoid erroneous data due to probe
insertion. After three baseline samples, rats
received an ip injection of vehicle (1% methyl-
cellulose) or ATR (100 or 200 mg/kg), and
ﬁve subsequent samples of perfusate were col-
lected. In order to probe characteristics of DA
release, a high potassium solution (91 mM
NaCl, 60 mM KCl, 1.2 mM CaCl2, and
1 mM MgCl2, pH 6.0–6.5) replaced the nor-
mal Ringer’s solution, and two samples were
collected under these conditions. Normal
Ringer’s solution was subsequently restored,
and two additional samples of perfusate were
collected. Collection vials contained 3.75 µL
0.1 M HClO4 solution. Collected samples
were immediately frozen at –80°C until
monoamine quantification by HPLC as
described above.
Histology. At the completion of micro-
dialysis sampling, rats were overdosed with
sodium pentobarbital and transcardially per-
fused with an isotonic saline solution followed
by 10% formaldehyde. Brains were postﬁxed
in 10% formalin overnight and then trans-
ferred to 30% sucrose. Brains were sectioned in
50 µm coronal slices, mounted, stained with
cresyl violet, and coverslipped. Cannula place-
ment for the microdialysis study was con-
ﬁrmed under microscopic analyses.
Statistical Analyses
We analyzed total locomotor activity counts,
body weight, and food consumption using
repeated-measures analysis of variance
(RMANOVA; treatment × time) followed by
post hoc tests as appropriate. Responsivity to
d-amphetamine and changes in neuro-
transmitter levels in various brain regions
were evaluated by one-way ANOVA with
post hoc assessments in the event of main
effects of treatment. To provide a more con-
servative analysis of changes in cell counts,
because counts in both regions were derived
from the same animals (brains), RMANOVA
was carried out based on changes in TH+ and
TH– cells in both SN and VTA (but not total
counts because that was the sum of the TH+
and TH– cells), followed by post hoc testing
as appropriate. We evaluated the effects of
ATR on microdialysis by RMANOVAs with
treatment and time as factors, followed by
post hoc evaluation in the case of main effects
or interactions. In all cases, statistical signiﬁ-
cance was deﬁned as p ≤ 0.05.
Results
Chronic ATR Exposure
Gross effects of treatment. No treatment-
related changes in body weight or food con-
sumption were detected at any point during
the course of the exposure (data not shown),
nor did any other signs of overt toxicity mani-
fest at any point.
Locomotor activity. In contrast to the
other time points of measurement, the assess-
ment of locomotor activity after 2 months of
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Figure 2. Horizontal locomotor activity (group mean as percentage of control ± SEM). (A) Effect of a
1-mg/kg dose of amphetamine sulfate administration on locomotor activity after 2 months of ATR expo-
sure. (B) Spontaneous locomotor activity measured at 3 months and 6 months of ATR exposure, and
2 weeks after cessation of ATR exposure. RMANOVA was followed by Fisher’s post hoc test. Absolute val-
ues (total counts ± SEM) for control animals are 8094.44 ± 1822.95 (amphetamine sulfate challenge after
2 months of ATR exposure); 3860.56 ± 703.66 (3 months of ATR exposure); 3168.60 ± 550.36 (6 months of ATR
exposure), and 4257.00 ± 588.45 (2 weeks after cessation of ATR). TX, treatment.
*Signiﬁcantly different from control group, p < 0.05 (n = 8–10 rats per treatment group).ATR exposure actually involved three ses-
sions, the ﬁrst two of which were preceded by
an ip injection of saline and the third by
1 mg/kg d-amphetamine sulfate. No treat-
ment-related changes in locomotor activity
were seen in either of the sessions preceded by
saline. However, in the third session, the
administration of d-amphetamine increased
locomotor activity of all three groups relative
to levels of activity after saline administration
[session 2; F(2,26) = 3.63, p < 0.041].
Additionally, these increases were modiﬁed by
ATR treatment in that the 10-mg/kg dose
further enhanced locomotor activity by an
additional 70% (Figure 2A) relative to the
increases in the 0- and 5-mg/kg groups, as
conﬁrmed in post hoc analyses.
At the remaining time points of measure-
ment, single locomotor activity sessions were
carried out in the absence of drug administra-
tion. Under these conditions, after 3 months
of ATR exposure, we found pronounced
increases in locomotor activity again at the
10-mg/kg dose of ATR [F(2,26) = 3.62,
p = 0.041], with levels of horizontal activity
that exceeded those of controls and the
5-mg/kg group by approximately 50%
(Figure 2B). These treatment-related effects
were also evident in the measurement of loco-
motor activity at the 6-month time point
[F(2,24) = 3.45, p = 0.048] and again when
measured 2 weeks after the termination of
ATR treatment [F(2,24) = 4.42, p = 0.024],
when levels remained at 40% above control.
Changes in monoamine levels. Measured
2 weeks after the termination of ATR expo-
sure, changes in DA content (Figure 3A) were
significant in striatum [F(2,23) = 3.61, p =
0.044] as well as in frontal cortex [F(2,21) =
3.82, p = 0.039]. Statistical analysis conﬁrmed
decreased levels of DA (~ 20%) in relation to
treatment in striatum, with post hoc assess-
ments indicating efficacy at the 10-mg/kg
ATR dose with a similar but nonsignificant
trend at 5 mg/kg. In contrast, levels of DA
were increased in prefrontal cortex in an
inverse U-shaped fashion, with post hoc
assessment conﬁrming a signiﬁcant increase at
5 mg/kg (by 30–40%), with levels declining
back toward control values at 10 mg/kg. Both
doses of ATR reduced serotonin (5-HT) lev-
els in hypothalamus [Figure 3B; F(2,21) =
5.19, p = 0.015] by 10–15%. Chronic ATR
exposure also decreased levels of NE in frontal
cortex [Figure 3C; F(2,21) = 3.84, p = 0.038],
with post hoc assessments showing the effect
with the 10-mg/kg dose producing reductions
of approximately 15–20%. Although a trend
toward increases in NE in nucleus accumbens
was suggested, it was associated with signifi-
cant variability and therefore not statistically
signiﬁcant.
We observed no changes in levels of the
metabolites of either 5-HT (5-hydroxyindole
acetic acid) or DA [DOPAC, homovanillic
acid (HVA)] or DA turnover (DOPAC:DA)
in any region.
Unbiased stereologic counts of cells in the
midbrain. Changes in numbers of cells in the
regions of the cell bodies of the two major
DA pathways are shown in Figure 4 for a
sample of five randomly selected animals
from each treatment group; numbers are
shown for TH+, TH–, and total cells in
SNpc and for corresponding data for the
VTA. Because these regions were from the
same brains, we performed a more conserva-
tive statistical analysis based on RMANOVA
to examine the impact of treatment on num-
bers of cells using counts of TH+ and TH–
from each region (not including total
counts). That analysis confirmed a signifi-
cant main effect of treatment [F(2,36) =
5.53, p = 0.02] and no interaction of treat-
ment by region, indicating that cell loss
occurred in both regions and, moreover, in
both TH+ and TH– cells. These effects were
primarily attributable to the 10-mg/kg dose
of ATR, as confirmed in subsequent
post hoc tests; the mean reductions in cell
numbers ranged from 9 to 13% in the
10-mg/kg dose group, whereas those in the
5-mg/kg group ranged from 0 to 3%.
Acute ATR Exposure
That systemic administration of ATR can
indeed directly affect brain dopaminergic sys-
tems was further confirmed in microdialysis
experiments. The impact of acute ip adminis-
tration of ATR (100 or 200 mg/kg) on levels
of DA in striatum, as assessed via microdialy-
sis, is presented in Figure 5A. Acutely, ATR
significantly decreased basal DA release, as
shown in the inset in Figure 5A [main effects:
treatment, F(2,19) = 4.88, p = 0.02; sampling
time: F(9,18) = 26.77, p < 0.0001; treatment
by time interaction: F(18,171) = 2.77,
p = 0.0003]. Post hoc tests conﬁrmed decreases
as measured at 90, 120, 150, and 180 min
postadministration of ATR. By 150 min, the
decrements averaged approximately 40% and
were seen in both the 100-mg/kg and the
200-mg/kg treatment groups.
We also observed a dose-dependent
decrease in DA release when the system was
challenged with 60 mM high potassium solu-
tion for 60 min [F(2,19) = 3.717, p = 0.0434].
Although the control group showed a 1,256%
increase from baseline in response to potassium
(210 min time point), corresponding values for
the 100-mg/kg and 200-mg/kg ATR groups
were 729 and 427%, respectively, from base-
line. After high potassium perfusion, the sys-
tem was flushed again with normal Ringer’s
solution; levels of DA declined in all groups,
and no treatment-related differences were evi-
dent during the remaining 60 min of sam-
pling. The increase in DA seen in the first
sample (240 min time point) after high potas-
sium infusion was due to dead volume of the
microdialysis sample collection system.
Analysis of striatal DOPAC levels in the
dialysates revealed only a signiﬁcant effect of
sampling time [F(9,18) = 13.735, p < 0.0001].
One-way ANOVA at each time point did not
show any difference among groups in DOPAC
concentration during the course of the experi-
ment (Figure 5B). Similarly, analysis of HVA
levels showed a signiﬁcant effect of sampling
time [F(9,18) = 6.074, p < 0.0001] but no
effect of group or group × sampling time inter-
action (Figure 5C).
Administration of vehicle (1% methyl-
cellulose) or 100 mg/kg ATR did not result in
acute observable effects in these rats, but some
rats injected with 200 mg/kg ATR exhibited
hypoactivity during the ﬁrst 2 hr after injection,
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Figure 3. Levels of DA (A), 5-HT (B), and NE (C; presented as the group mean as a percentage of control ± SEM) in striatum, prefrontal cortex, nucleus accumbens,
and hypothalamus 2 weeks after cessation of ATR exposure (6 months). One-way ANOVAs for each region were followed by Fisher’s post hoc test. Absolute values
(ng/mg protein ± SEM) for control animals are, for DA: 122.25 ± 8.54 (striatum), 2.83 ± 0.21 (prefrontal cortex), 6.09 ± 0.55 (hypothalamus), 78.70 ± 7.12 (nucleus
accumbens); for 5-HT: 2.46 ± 0.27 (striatum), 15.45 ± 1.31 (prefrontal cortex), 14.44 ± 0.46 (hypothalamus), 8.22 ± 0.68 (nucleus accumbens); and for NE: 11.44 ± 0.77
(prefrontal cortex), 34.65 ± 1.67 (hypothalamus), 1.63 ± 0.14 (nucleus accumbens). 
*Signiﬁcantly different from control group, p < 0.05 (n = 7–10 rats per treatment group).after which levels appeared normal. Histologic
analysis confirmed that cannula placement
was appropriately located in dorsal striatum
for all rats.
Discussion
The present study demonstrates that sustained
low-level ATR exposure in diet can adversely
affect both major long-length dopaminergic
tracts of the central nervous system, resulting
in persistent increases in locomotor activity,
alterations in responsivity to the indirect DA
agonist amphetamine, changes in monoamine
levels, and, ultimately, loss of neurons in the
midbrain. Thus, adverse effects of ATR are
not restricted to endocrine and reproductive
systems or to hypothalamic regions of brain.
The effects observed here cannot be ascribed
to acute toxicity because the half-life of ATR
in tissue ranges from 31.3 to 38.6 hr, and
95% of the ATR administered is excreted
within 7 days of dosing, whereas changes in
monoamines and numbers of neurons were
measured 2 weeks posttreatment. Moreover,
the doses used here did not produce any
changes in body weight or food consumption
or any signs of overt toxicity.
The observations of protracted changes in
neurotransmitter levels coupled with neuronal
loss have particular significance, given the
critical roles of the nigrostriatal and meso-
corticolimbic dopaminergic systems in con-
trolling fine motor behavior and complex
cognitive function, respectively (Clark et al.
2004; Crossman 2000; Remy and Samson
2003). Dysfunctions of dopaminergic systems
include Parkinson’s disease, schizophrenia,
attention deficit disorder, and learning and
memory impairments. Collectively, the pre-
sent findings raise the possibility that ATR
exposure could be a contributory risk factor
for such disorders.
Chronic ATR exposure caused cell loss not
only to TH+ immunoreactive cells but also to
TH– cells in the VTA and SNpc. The non-
dopaminergic neuronal subpopulation in these
regions includes GABAergic (Deniau et al.
1978), calbindin (Gerfen et al. 1985), and
cholecystokinin-like immunoreactive neurons
(Seroogy and Fallon 1989). The lack of selec-
tivity of effects makes it likely that ATR will
exhibit neurotoxicity, including cytotoxicity to
other neuronal populations in other brain
regions, although other regions were not
examined in the present study. Additionally,
ATR may exert neurotoxic effects on other cell
types of the brain as well, such as glial cells.
The specificity and mechanism(s) of ATR
effects within the central nervous system
remain to be determined, and such assess-
ments are clearly warranted based on the ﬁnd-
ings presented here.
Chronic ATR increased locomotor activ-
ity, an effect present after 3 months of expo-
sure, persisted for 6 months and was still
evident even 2 weeks after cessation of expo-
sure. Moreover, rats treated for 2 months
with 10 mg/kg ATR exhibited an enhanced
locomotor activity response to a d-ampheta-
mine challenge. Amphetamine is known to
promote the release of DA and a decrease in
its re-uptake into the presynaptic terminal
(Cooper et al. 2003). Thus, the increases in
locomotor activity could reﬂect ATR-induced
up-regulation of striatal DA receptors, as
might be expected to occur in response to the
corresponding reduction in basal DA levels
(Figure 3A) or DA release produced by ATR
(Figure 5A). Placement in a novel environ-
ment such as the locomotor activity chamber
could increase DA, activating up-regulated
DA receptors and thereby producing hyper-
activity (Badiani et al. 1998), a hypothesis in
agreement with the increases in locomotor
activity induced by amphetamine sulfate
(Mao et al. 2001).
The locomotor hyperactivity observed
here differs from ﬁndings of a previous study
in which 1,000 mg/kg ATR administered for
4–11 days decreased rearing in the open ﬁeld
(Ugazio et al. 1991). Such decreases could
reflect acute toxicity of a high dose of ATR
because the chemical was administered imme-
diately before the behavioral evaluation in that
study, coupled with a decline in DA release
that would accompany its administration and
be expected to reduce activity levels, as was
observed.
The reductions noted here in levels of
DA, NE, and 5-HT observed, respectively, in
striatum, prefrontal cortex, and hypothala-
mus at the 10-mg/kg ATR dose could be due
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Figure 4. Numbers of TH+, TH–, or total cells in SNpc (top row) or in VTA (bottom row) measured using unbiased stereology and determined 2 weeks after termination
of ATR treatment. Each point represents the value for an individual animal, with n = 5 randomly selected per treatment group counted. Black bars represent group
medians.to inhibitory effects on synthesis in these
monoamine pathways. Precursors of DA and
NE (tyrosine) and of 5-HT (tryptophan)
undergo the same hydroxylation process via
TH or tryptophan hydroxylase, respectively.
Both enzymes are pteridin-dependent aromatic
amino acid hydroxylases and are highly homol-
ogous, reﬂecting a common evolutionary ori-
gin from a single genetic locus (Cooper et al.
2003). In an in vitro study using PC12 cells in
which NE and DA were decreased by ATR,
the NE effect was reversed when cells were co-
incubated with agents known to enhance tran-
scription and phosphorylation of dopamine
β-hydroxylase and TH (Das et al. 2003), con-
sistent with the possibility that ATR may have
inhibitory effects on these enzymes.
Previous studies have reported changes in
hypothalamic DA and/or NE levels after
acute ATR administration at 100 mg/kg by
gavage to male rats (Cooper et al. 1998). We
did not observe such changes in the chronic
exposure paradigm used here, a difference
that could reflect initiation of compensatory
mechanisms to maintain a constant produc-
tion of these neurotransmitters under condi-
tions of chronic exposure. Alternatively,
catecholamine levels were determined in spe-
cific hypothalamic nuclei in that study,
whereas here we examined the hypothalamus
in its entirety, thus possibly diluting any
regional changes (Cooper et al. 1998).
Chronic ATR exposure did decrease
hypothalamic 5-HT levels, effects consistent
with its known alterations of neuroendocrine
systems, including the release of LH and pro-
lactin. Serotonergic neurons from the dorsal
and medial raphe nuclei project to hypothala-
mus, activating the hypothalamo–pituitary–
adenocortical (HPA) and the hypothalamo–
pituitary–gonadal (HPG) axes in the rat
(Fuller 1996; Jorgensen et al. 1998). Agents
that disrupt 5-HT transmission are known to
alter the HPA and HPG axes (Fuller 1996;
Fuller and Snoddy 1990). Furthermore, selec-
tive degeneration of the midbrain dorsal and
ventromedial region of the hypothalamus
induced by 5,7-dihydroxytryptamine reduces
LH levels (van de Kar et al. 1980). Taken
together, it can be inferred that reductions in
hypothalamic 5-HT resulting from ATR
could affect both the HPA and HPG axes and
thereby alter other organ systems of the body
with which these systems interact.
DA and NE alterations in prefrontal cortex
are also notable given the critical role of this
structure in mediating executive function,
including working memory (Dreher et al.
2002). Dysfunction of this region is also
involved in cognitive deficits, altered stress
responsivity, hyperactivity disorder, and schizo-
phrenia (Mostofsky et al. 2002; Tam and Roth
1997; Viggiano et al. 2003). An increase in
cortical DA levels, such as observed at
5 mg/kg, could be due to an increase in DA
synthesis, decreased degradation, or altered
re-uptake. It is worth noting that autoreceptors
on DA terminals in the prefrontal cortex regu-
late release but not synthesis of DA (Cooper
et al. 2003), which may explain why aug-
mented DA concentrations in this region are
not corrected after ATR exposure.
Findings from the microdialysis compo-
nent of these experiments are consistent with
such an assertion and show alterations in the
dynamics of DA in striatum after acute ATR
treatment. A dose-dependent decrease in stri-
atal DA release as observed here would nor-
mally trigger compensatory mechanisms such
as decreased re-uptake rate and increased pro-
duction and release of DA. As is evident from
Figure 5, none of these compensatory mecha-
nisms appears to be operative, at least within
the time frame encompassed by these experi-
ments.
The observed decline in both basal and
stimulated DA release could have several
explanations. First, it could reﬂect a general-
ized inhibition of DA synthesis, given the
absence of group differences at the end of the
experiment. DA is distributed mainly in two
functional presynaptic compartments, a cyto-
plasmic pool and a vesicular pool. Potassium-
induced release is Ca2+ dependent and occurs
from the vesicular pool (Du et al. 1999), which
is the newly synthesized pool (Lamensdorf
et al. 1996). Another possibility is that ATR
decreases the ﬁring rate of striatal and/or SN
neurons, decreasing DA release. Additionally,
TH exists in two kinetic forms, with differen-
tial afﬁnities for tetrahydrobiopterin (cofactor
for TH). The proportion of TH in the high-
afﬁnity state appears to be a function of neu-
ronal ﬁring rate (Cooper et al. 2003). A dose of
100 mg/kg ATR decreased cerebellar cell ﬁring
rate after 60 and 90 min, with rates returning
to normal by 180 min; this inhibitory effect
lasted up to 180 min after exposure to
200 mg/kg ATR (Podda et al. 1997). ATR
could also be acting on ionotropic GABA
receptors. Binding of RO15-4513 (an inverse
agonist of the GABAA receptor benzodiazepine
site) was inhibited when cortical membranes
were incubated with ATR (Shafer et al. 1999).
This would increase the inﬂux of chloride ions,
leading to hyperpolarization of cells, prevent-
ing depolarization that would, in turn, decrease
DA release.
No changes in levels of the DA metabo-
lites DOPAC and HVA were observed in the
microdialysis component of this study,
although DA levels were altered. DA is con-
verted to DOPAC intraneuronally after
re-uptake, whereas extraneuronal DA is con-
verted to HVA by the enzymes catechol-O-
methyltransferase and monoamine oxidase.
The lack of change in DOPAC and HVA
could reflect the relatively modest nature of
the changes in DA, leaving a sufﬁciently high
concentration of DA in the intracellular
space to maintain constant levels of DOPAC
and HVA production. Further, DA re-uptake
was not impaired. The decreases in DOPAC
and reductions in extracellular DOPAC and
HVA after potassium stimulation across sam-
pling time in the microdialysis component of
this study agree with results of other such
studies (Holson et al. 1998; Robinson and
Camp 1991; Stanford et al. 2000; Westerink
and Tuinte 1986) and may reflect initial
damage caused by the probe insertion, which
recovers after several hours. The decrease in
DOPAC levels that occurs with the increase
in extracellular DA after potassium perfusion
is thought to reﬂect a decrease in intracellular
DA metabolism by monoamine oxidase
(Camarero et al. 2002).
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+100-mg and *200-mg groups signiﬁcantly different from control group, p < 0.05 (n = 7–8 rats per treatment group).At the present time, the health-related
impacts that ATR exposures may exert in
human populations remain unknown.
Assessments of occupational exposures have
been limited, and systematic studies of envi-
ronmental exposures have not been under-
taken. Although the doses of ATR used in
these studies are higher than those estimated
for human exposures, additional considerations
must be applied to such comparisons. First,
data projecting human exposure are always
limited because they are dependent upon when
exposures occurred relative to the time of
measurement and do not provide measure-
ment of the tissue of interest (i.e., the brain) in
such cases. Second, the doses used here are low
for the experimental species (rat), being consis-
tent with previously reported NOAEL and
LOAEL levels. Furthermore, even at these lev-
els, the doses may not have been as high as
administered because probably not all the ATR
ingested would have been absorbed; a portion
of it could have been easily eliminated through
the feces, suggesting that lower actually
absorbed doses could underlie the deleterious
effects observed in this study.
In summary, the collective ﬁndings from
this study demonstrate that ATR may have
broad effects on brain monoamine systems and
thereby influence a wide range of behavioral
functions. Clearly, additional studies are
needed to unravel the targets of ATR and the
mechanism(s) of its effects, as well as the ulti-
mate human health consequences of such
exposures for behavioral and/or neurologic
dysfunctions.
REFERENCES
Adgate JL, Barr DB, Clayton CA, Eberly LE, Freeman NC,
Lioy PJ, et al. 2001. Measurement of children’s exposure
to pesticides: analysis of urinary metabolite levels in a
probability-based sample. Environ Health Perspect
109:583–590.
Badiani A, Oates MM, Day HE, Watson SJ, Akil H, Robinson TE.
1998. Amphetamine-induced behavior, dopamine release,
and c-fos mRNA expression: modulation by environmental
novelty. J Neurosci 18:10579–10593.
Barlow BK, Richﬁeld EK, Cory-Slechta DA, Thiruchelvam M. 2004.
A fetal risk factor for Parkinson’s disease. Dev Neurosci
26:11–23.
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M,
Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide
exposure reproduces features of Parkinson’s disease. Nat
Neurosci 3:1301–1306.
Birnbaum LS, Fenton SE. 2003. Cancer and developmental
exposure to endocrine disruptors. Environ Health Perspect
111:389–394.
Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M. 2002.
Chronic but not acute treatment with a metabotropic gluta-
mate 5 receptor antagonist reverses the akinetic deﬁcits in
a rat model of parkinsonism. J Neurosci 22:5669–5678.
Camarero J, Sanchez V, O’Shea E, Green AR, Colado MI. 2002.
Studies, using in vivo microdialysis, on the effect of the
dopamine uptake inhibitor GBR 12909 on 3,4-methylene-
dioxymethamphetamine (‘ecstasy’)-induced dopamine
release and free radical formation in the mouse striatum.
J Neurochem 81:961–972.
Catenacci G, Barbieri F, Bersani M, Ferioli A, Cottica D, Maroni
M. 1993. Biological monitoring of human exposure to
atrazine. Toxicol Lett 69:217–222.
Clark L, Cools R, Robbins TW. 2004. The neuropsychology of
ventral prefrontal cortex: decision-making and reversal
learning. Brain Cogn 55:41–53.
Clayton CA, Pellizzari ED, Whitmore RW, Quackenboss JJ,
Adgate J, Sefton K. 2003. Distributions, associations, and
partial aggregate exposure of pesticides and polynuclear
aromatic hydrocarbons in the Minnesota Children’s
Pesticide Exposure Study (MNCPES). J Expo Anal Environ
Epidemiol 13:100–111.
Colborn T, Short P. 1999. Pesticide use in the U.S. and policy
implications: a focus on herbicides. Toxicol Ind Health
15:240–275.
Cooper JR, Bloom FE, Roth RH. 2003. The Biochemical Basis of
Neuropharmacology. 8th ed. New York:Oxford University
Press.
Cooper RL, Stoker TE, Goldman JM, Parrish MB, Tyrey L. 1996.
Effect of atrazine on ovarian function in the rat. Reprod
Toxicol 10:257–264.
Cooper RL, Stoker TE, McElroy WK, Heien J. 1998. Atrazine
(ATR) disrupts hypothalamic catecholamines and pituitary
function [Abstract]. Toxicol Sci 42:160.
Cooper RL, Stoker TE, Tyrey L, Goldman JM, McElroy WK. 2000.
Atrazine disrupts the hypothalamic control of pituitary-
ovarian function. Toxicol Sci 53:297–307.
Crossman AR. 2000. Functional anatomy of movement disorders.
J Anat 196:519–525.
Das PC, McElroy WK, Cooper RL. 2000. Differential modulation of
catecholamines by chlorotriazine herbicides in pheo-
chromocytoma (PC12) cells in vitro. Toxicol Sci 56:324–331.
Das PC, McElroy WK, Cooper RL. 2003. Potential mechanisms
responsible for chlorotriazine-induced alterations in cate-
cholamines in pheochromocytoma (PC12) cells. Life Sci
73:3123–3138.
Deniau JM, Hammond C, Riszk A, Feger J. 1978. Electro-
physiological properties of identiﬁed output neurons of the
rat substantia nigra (pars compacta and pars reticulata):
evidences for the existence of branched neurons. Exp
Brain Res 32:409–422.
Dreher JC, Guigon E, Burnod Y. 2002. A model of prefrontal cortex
dopaminergic modulation during the delayed alternation
task. J Cogn Neurosci 14:853–865.
Du W, Aloyo VJ, Pazdelski PS, Harvey JA. 1999. Effects of pre-
natal cocaine exposure on amphetamine-induced dopamine
release in the caudate nucleus of the adult rabbit. Brain Res
836:194–198.
Eldridge JC, Wetzel LT, Stevens JT, Simpkins JW. 1999. The
mammary tumor response in triazine-treated female rats:
a threshold-mediated interaction with strain and species-
speciﬁc reproductive senescence. Steroids 64:672–678.
Epstein J, Stern E, Silbersweig D. 1999. Mesolimbic activity
associated with psychosis in schizophrenia. Symptom-
speciﬁc PET studies. Ann NY Acad Sci 877:562–574.
Friedmann AS. 2002. Atrazine inhibition of testosterone produc-
tion in rat males following peripubertal exposure. Reprod
Toxicol 16:275–279.
Fuller RW. 1996. Serotonin receptors involved in regulation of
pituitary-adrenocortical function in rats. Behav Brain Res
73:215–219.
Fuller RW, Snoddy HD. 1990. Serotonin receptor subtypes
involved in the elevation of serum corticosterone concentra-
tion in rats by direct- and indirect-acting serotonin agonists.
Neuroendocrinology 52:206–211.
Gammon DW, Aldous CN, Carr WC Jr, Sanborn JR, Pfeifer KF.
2005. A risk assessment of atrazine use in California: human
health and ecological aspects. Pest Manag Sci 61:331–355;
doi: 10.1002/ps.1000 [Online 17 January 2005].
Gerfen CR, Baimbridge KG, Miller JJ. 1985. The neostriatal
mosaic: compartmental distribution of calcium-binding
protein and parvalbumin in the basal ganglia of the rat and
monkey. Proc Natl Acad Sci USA 82:8780–8784.
Holson RR, Gazzara RA, Gough B. 1998. Declines in stimulated
striatal dopamine release over the first 32 h following
microdialysis probe insertion: generalization across
releasing mechanisms. Brain Res 808:182–189.
Institute of Laboratory Animal Resources. 1996. Guide for the
Care and Use of Laboratory Animals. Washington,
DC:National Academy Press. Available: http://oacu.od.nih.
gov/regs/guide/guidex.htm [accessed 20 April 2005].
Jorgensen H, Knigge U, Kjaer A, Vadsholt T, Warberg J. 1998.
Serotonergic involvement in stress-induced ACTH release.
Brain Res 811:10–20.
Lamensdorf I, Youdim MB, Finberg JP. 1996. Effect of long-term
treatment with selective monoamine oxidase A and B
inhibitors on dopamine release from rat striatum in vivo.
J Neurochem 67:1532–1539.
Laws SC, Ferrell JM, Stoker TE, Schmid J, Cooper RL. 2000. The
effects of atrazine on female wistar rats: an evaluation of the
protocol for assessing pubertal development and thyroid
function. Toxicol Sci 58:366–376.
Lioy PJ, Edwards RD, Freeman N, Gurunathan S, Pellizzari ED,
Adgate JL, et al. 2000. House dust levels of selected insec-
ticides and a herbicide measured by the EL and LWW
samplers and comparisons to hand rinses and urine
metabolites. J Expo Anal Environ Epidemiol 10:327–340.
MacLennan PA, Delzell E, Sathiakumar N, Myers SL. 2003.
Mortality among triazine herbicide manufacturing workers.
J Toxicol Environ Health A 66:501–517.
Mao L, Conquet F, Wang JQ. 2001. Augmented motor activity
and reduced striatal preprodynorphin mRNA induction in
response to acute amphetamine administration in
metabotropic glutamate receptor 1 knockout mice.
Neuroscience 106:303–312.
Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann
WE. 2002. Smaller prefrontal and premotor volumes in
boys with attention-deficit/hyperactivity disorder. Biol
Psychiatry 52:785–794.
Paxinos G, Watson C. 1986. The Brain Stereotaxic Coordinates.
2nd ed. New York:Academic Press.
Podda MV, Deriu F, Solinas A, Demontis MP, Varoni MV,
Spissu A, et al. 1997. Effect of atrazine administration on
spontaneous and evoked cerebellar activity in the rat.
Pharmacol Res 36:199–202.
Reeves R, Thiruchelvam M, Baggs RB, Cory-Slechta DA. 2003.
Interactions of paraquat and triadimefon: behavioral and
neurochemical effects. Neurotoxicology 24:839–850.
Remy P, Samson Y. 2003. The role of dopamine in cognition:
evidence from functional imaging studies. Curr Opin
Neurol 16(suppl):S37–S41.
Robinson TE, Camp DM. 1991. The effects of four days of con-
tinuous striatal microdialysis on indices of dopamine and
serotonin neurotransmission in rats. J Neurosci Methods
40:211–222.
Rooney AA, Matulka RA, Luebke RW. 2003. Developmental
atrazine exposure suppresses immune function in male, but
not female Sprague-Dawley rats. Toxicol Sci 76:366–375.
Sathiakumar N, Delzell E. 1997. A review of epidemiologic stud-
ies of triazine herbicides and cancer. Crit Rev Toxicol
27:599–612.
Sathiakumar N, Delzell E, Cole P. 1996. Mortality among workers
at two triazine herbicide manufacturing plants. Am J Ind
Med 29:143–151.
Seroogy KB, Fallon JH. 1989. Forebrain projections from
cholecystokininlike-immunoreactive neurons in the rat
midbrain. J Comp Neurol 279:415–435.
Shafer TJ, Ward TR, Meacham CA, Cooper RL. 1999. Effects of
the chlorotriazine herbicide, cyanazine, on GABA(A) recep-
tors in cortical tissue from rat brain. Toxicology 142:57–68.
Stanford JA, Giardina K, Gerhardt GA. 2000. In vivo micro-
dialysis studies of age-related alterations in potassium-
evoked overflow of dopamine in the dorsal striatum of
Fischer 344 rats. Int J Dev Neurosci 18:411–416.
Stoker TE, Guidici DL, Laws SC, Cooper RL. 2002. The effects of
atrazine metabolites on puberty and thyroid function in the
male Wistar rat. Toxicol Sci 67:198–206.
Stoker TE, Laws SC, Guidici DL, Cooper RL. 2000. The effect of
atrazine on puberty in male Wistar rats: an evaluation in
the protocol for the assessment of pubertal development
and thyroid function. Toxicol Sci 58:50–59.
Tam SY, Roth RH. 1997. Mesoprefrontal dopaminergic neurons:
can tyrosine availability influence their functions?
Biochem Pharmacol 53:441–453.
Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-
Slechta DA. 2000a. Potentiated and preferential effects of
combined paraquat and maneb on nigrostriatal dopamine
systems: environmental risk factors for Parkinson’s disease?
Brain Res 873:225–234.
Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK.
2004. Risk factors for dopaminergic neuron loss in human
alpha-synuclein transgenic mice. Eur J Neurosci 19:845–854.
Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-
Slechta DA. 2000b. The nigrostriatal dopaminergic system
as a preferential target of repeated exposures to com-
bined paraquat and maneb: implications for Parkinson’s
disease. J Neurosci 20:9207–9214.
Ugazio G, Bosio A, Burdino E, Ghigo L, Nebbia C. 1991.
Lethality, hexobarbital narcosis and behavior in rats
exposed to atrazine, bentazon or molinate. Res Commun
Chem Pathol Pharmacol 74:349–361.
U.S. EPA. 2001. Atrazine: Toxicology Chapter of the
Article | Rodriguez et al.
714 VOLUME 113 | NUMBER 6 | June 2005 • Environmental Health PerspectivesArticle | Atrazine alters function in monoamine systems
Environmental Health Perspectives • VOLUME 113 | NUMBER 6 | June 2005 715
Reregistration Eligibility Decision. Revised. ed.
Washington, DC:Ofﬁce of Prevention, Pesticides and Toxic
Substances, U.S. Environmental Protection Agency.
Available: http://www.epa.gov/oppsrrd1/reregistration/
atrazine/tox_chapter.pdf [accessed 11 July 2003].
van de Kar LD, Lorens SA, Vodraska A, Allers G, Green M,
Van Orden DE, et al. 1980. Effect of selective midbrain and
diencephalic 5,7-dihydroxytryptamine lesions on serotonin
content in individual preopticohypothalamic nuclei and on
serum luteinizing hormone level. Neuroendocrinology
31:309–315.
Viggiano D, Vallone D, Ruocco LA, Sadile AG. 2003. Behavioural,
pharmacological, morpho-functional molecular studies
reveal a hyperfunctioning mesocortical dopamine system
in an animal model of attention deficit and hyperactivity
disorder. Neurosci Biobehav Rev 27:683–689.
Westerink BH, Tuinte MH. 1986. Chronic use of intracerebral
dialysis for the in vivo measurement of 3,4-dihydroxy-
phenylethylamine and its metabolite 3,4- dihydroxyphenyl-
acetic acid. J Neurochem 46:181–185.